Safety and Effectiveness Study of OR3O™ Dual Mobility System in THA
← catalyst calendarSponsored by Smith & Nephew, Inc. (industry) · SNN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
177actual
Sites
12
Countries
Australia, Canada, Hong Kong +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-07-27 | actual | When the study began enrolling |
| Primary completion | 2026-02-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2035-01-31 | estimated | The whole study's end, after follow-up |
| First posted | 2020-03-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Degeneration of the Hip Joint
- Revision of the Hip Joint
Interventions
- Device: Primary Total Hip Arthroplasty
- Device: Revision Total Hip Arthroplasty
Primary outcome
what the primary-completion date above is the date OFSurvivorship of Primary Total Hip Arthroplasty (THA)
measured 2 years
Permalink · SNN's whole pipeline · Catalyst calendar · Every registered study · What changed